Evidence map›Paper›PMID 40908756›Full record

ArticleActa dermato-venereologica2025

Exploring the Risk Factors of Rosacea Exacerbation Associated with COVID-19 Infection or Vaccination: A Cross-sectional Study.

Xidie Yin, Yiting Zhao, Liyuan Zhou, Xiaojing Liu, Yu Yan, Zhi Cao, Shu Zhan Shen, Qihang Chang, Yajing Cao, Xiuli Wang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xidie Yin *Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Yiting Zhao *Institute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Liyuan ZhouInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Xiaojing LiuInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Yu YanInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhi CaoInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Shu Zhan ShenInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Qihang ChangInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
Yajing CaoInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. 125852634@qq.com.
Xiuli WangInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. wangxiuli_1400023@tongji.edu.cn.
Peiru WangInstitute of Photomedicine, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. wangpeiru@tongji.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 can affect the skin, with rosacea flare-ups reported after infection or vaccination. This study compared rosacea patients with and without post-COVID-19 exacerbation to identify contributing factors. A customized electronic questionnaire was administered to rosacea patients, gathering COVID-19 infection/vaccination status, demographics, and rosacea features. Participants were classified by post-COVID-19 rosacea exacerbation vs none. Multivariable logistic regression identified risk factors. Finally, a total of 104 patients were analysed; 15.4% experienced rosacea exacerbation after COVID-19 vaccination and 28.8% after infection. Comorbidities such as metabolic diseases or allergic diseases were associated with a higher risk of rosacea exacerbation after vaccination or infection (OR = 11.083, 95% CI: 1.136-108.135). Burning and stinging symptoms predicted higher exacerbation risk after vaccination (OR = 8.978, 95% CI 1.968-40.969). Papulopustular rosacea was associated with lower risk (OR = 0.276, 95% CI: 0.066-1.160). Higher body mass index (BMI) was associated with lower exacerbation risk after vaccination (OR = 0.646, 95% CI 0.450-0.928) and infection (OR = 0.731, 95% CI: 0.572-0.933). Frequent rosacea episodes increased exacerbation risk after infection (OR = 8.288, 95% CI: 2.044-33.608). In conclusion, lower BMI was associated with higher risk of rosacea exacerbation after COVID-19 vaccination or infection. Patients with burning and stinging symptoms or a non-papulopustular subtype were more likely to experience exacerbation after vaccination.

Indexed as

COVID-19COVID-19 VaccinesRosaceaVaccinationAdultAgedCross-Sectional StudiesDisease ProgressionFemaleHumansMaleMiddle AgedRisk FactorsSARS-CoV-2Symptom Flare UpCOVID-19 Vaccines

Identifiers

PMID40908756
PMCPMC12427583

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.